Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson’s disease
We tested in a translational approach the usefulness of plasma creatine kinase (CK) as an objective biomarker for levodopa-induced dyskinesia (LID). Plasma CK levels were measured in five dyskinetic parkinsonian non-human primates (NHP) and in ten PD patients with LID who participated in a treatment trial with simvastatin. Plasma CK levels were increased in dyskinetic NHP and correlated with LID severity while they were not affected by LID severity in PD patients.
KeywordsParkinson’s disease Levodopa-induced dyskinesia Biomarker Creatine kinase
The Simvastatin trial was funded by a Michael J. Fox Foundation Clinical Intervention Award 2008.
The Simvastatin trial was funded by a M. J. Fox Foundation Clinical Intervention Award 2008.
Compliance with ethical standards
Conflict of interest
None of the authors has a conflict of interest in relation to the research covered in the article. Outside the present study (past 12 months), QL and MG have nothing to declare. AD declares a grant from the Fondation pour la recherche médicale (FDM201806005951). FT has received a travel grant from ORKYN and research grants from the French Health Ministry (PHRC). EB has an equity stake in Motac holding Ltd and receives consultancy payments from Motac Neuroscience Ltd. Current grant support includes Agence Nationale de la Recherche, China Science Fund, Michael J Fox Foundation for Parkinson Research, France Parkinson, Fondation de France, Medical Research Council, Innovative Medicines Initiative (H2020, IMPRIND), IDEX Bordeaux, COEN, MSA Coalition, Rotary Foundation, Nouvelle-Aquitaine Regional Council, and LABEX Brain. OR has received grants from Agence Nationale de la Recherche (ANR), CHU de Toulouse, France-Parkinson, INSERM-DHOS Recherche Clinique Translationnelle, MJFox Foundation, Programme Hospitalier de Recherche Clinique, European Commission (FP7, H2020) and has served as scientific consultant for AbbVie, Adamas, Acorda, Addex, AlzProtect, Apopharma, Astra Zeneca, Bial, Biogen, Britannia, Clevexel, Cynapsus, INC Research, Lundbeck, Merck, MundiPharma, Neuroderm, Novartis, Oxford Biomedica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Sanofi, Servier, Teva, UCB, XenoPort, Zambon. EB has an equity stake in Motac holding Ltd and receives consultancy payments from Motac Neuroscience Ltd. Current grant support includes Agence Nationale de la Recherche, China Science Fund, Michael J Fox Foundation for Parkinson Research, France Parkinson, Fondation de France, Medical Research Council, Innovative Medicines Initiative (H2020, IMPRIND), IDEX Bordeaux, COEN, MSA Coalition, Rotary Foundation, Nouvelle-Aquitaine Regional Council, and LABEX Brain. WGM has received fees for editorial activities with Springer Nature, honoraria for consultancy activities from Sanofi, Lundbeck and Affiris, teaching honoraria from UCB, honoraria from MDS, as well as research support from the Michael J Fox Foundation, the University Hospital Bordeaux, the French Health Ministry, the European Community, ANR, ARAMISE, PSP-France, MSA Coalition, LABEX Excellence Initiative.
All animal experiments were performed in accordance with the European Union directive of September 22, 2010 (2010/63/EU) on the protection of animals used for scientific purposes in an AAALAC-accredited facility following acceptance of study design by the Institute of Lab Animal Science (Chinese Academy of Science, Beijing, China).
Written consent of all subjects of the simvastatin trial was obtained prior to enrolment and following ethics approval (CPP Sud-Ouest et Outremer 3).
- Khan FY (2009) Rhabdomyolysis: a review of the literature. Neth J Med 67:272–283Google Scholar
- Koch AJ, Pereira R, Machado M (2014) The creatine kinase response to resistance exercise. J Musculoskelet Neuronal Interact 14:68–77Google Scholar
- Tison F et al (2013) Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (“n-of-1”) exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson’s disease patients. Parkinsonism Relat Disord 19:416–421. https://doi.org/10.1016/j.parkreldis.2012.12.003 CrossRefGoogle Scholar